464
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial)

, , , , , , , , , , , , & show all
Pages 200-207 | Received 24 Jun 2016, Accepted 30 Sep 2016, Published online: 08 Nov 2016
 

Abstract

Background: Daptomycin is an optimal choice for outpatient parenteral antibiotic therapy (OPAT) because of its safety, once-daily administration and its activity against Gram-positive bacteria. Although daptomycin is increasingly being used in OPAT, limited information about its safety in this scenario is available.

Methods: We performed a prospective multicentre pilot study to evaluate the safety of daptomycin in outpatients with proved or suspected Gram-positive infections (DAPTODOM). The primary objective was to evaluate the safety and the secondary objective to evaluate the efficacy in OPAT. We also looked at the development of daptomycin resistance in those cases with microbiological failure.

Results: We included 54 patients from 12 Spanish hospitals, 67% male with a mean age of 67.1 years. Most patients (87%) had chronic underlying diseases. The main reason for inclusion was skin and soft-tissue infections in 52%, followed by bacteremia or endocarditis in 34%. Staphylococcus aureus accounted for 44% of the isolates (24% were methicillin-resistant), coagulase-negative staphylococci 15% and enterococci 7%. Two patients (4%) had to be readmitted because of complications; only one patient had an adverse effect related to daptomycin (increase in serum creatine kinase levels), which disappeared after discontinuation (2%). At the end of follow-up, 96% of patients had good outcome and only 4% of patients did not have a clinical or microbiological cure. The use of a 2-minute bolus in 18 cases was not associated with adverse effects.

Conclusions: Daptomycin was safe and efficacious in outpatients with Gram-positive bacterial infections and can be administered in 2-minute bolus infusion.

Disclosure statement

C.C. has received consulting honoraria and/or research grants from Novartis, Gilead, Pfizer, Astellas and Merck. J.M.M. has received consulting honoraria and/or research grants from Abbvie, Bristol-Myers Squibb, Cubist, Gilead Sciences, Merck, Novartis and ViiV Healthcare. P.S. has received consulting honoraria from Novartis. V.G.R. has received consulting honoraria from MSD and Novartis. M.M. has received honoraria from Merck, Novartis and Boehringer Ingelheim. All other authors have no conflicts of interest. During the study period M.M. was working at Hospital Universitari Joan XXIII, Tarragona, Spain.

Funding

This work was supported in part by grants from Novartis, Spain and the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008) (Madrid, Spain). Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid (Spain) granted to JMM a personal intensification research grant # INT15/00168 during 2016.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 174.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.